IQVIA Report: "Clinical Trial Shares Decline in Europe, Surge in North America and China"

english

"Global Clinical Trials Shift from Europe to US and China"

The focus of global clinical trials is shifting from Europe to the United States and China, according to a recent market analysis. IQVIA, a global healthcare consulting firm, released a…

Market Share Drops to 82% in May... Challenges from Samsung Bioepis and Celltrion

english

Biosimilar Onslaught Dents Global Blockbuster Humira

The dominance of the autoimmune disease treatment Humira (active ingredient: adalimumab), once the world's best-selling drug, is waning. Sandoz's biosimilar Hyrimoz has rapidly gained market share,…

Epkinly Approved as Third-Line Treatment for Diffuse Large B-Cell Lymphoma in Korea

english

A New Treatment Option Emerges for Non-Hodgkin's Lymphoma

A new treatment option for managing refractory blood cancer, specifically Diffuse Large B-Cell Lymphoma (DLBCL), has completed its approval process in Korea. This approval primarily…

Shin Dong-kuk "Discussing Responsibility Management and Professional Management Integration with Two Brothers"

english

Hanmi Pharmaceutical Group Declares End to Management Dispute

The management dispute within Hanmi Pharmaceutical Group that has heated up the pharmaceutical and biotech industry for over 6months this year has come to an end. On the 10th, Lim Jong-yoon, an…

K-CAB's U.S. Phase 3 Clinical Trial Results Expected in the Second Half

english

Reasons to Watch HK Inno.N in the Second Half of the Year

HK Inno.N Corporation is emerging as a company to watch in the second half of the year, following strong performance and promising U.S. clinical trial results. On the 9th, the securities industry…